Bora Biologics enters animal health with Protect antibody manufacturing deal

12/11/2026

A long-term partnership brings development and manufacturing support to at least three veterinary antibody programmes for US and global markets.

Bora Biologics is entering the animal-health market through a long-term development and manufacturing partnership with Protect Animal Health, creating an industrial route for veterinary antibody programmes that would otherwise need to build specialist biologics capabilities independently.

The agreement covers at least three programmes: two monoclonal-antibody candidates and one bispecific-antibody candidate. Bora will support the work from cell-line and process development through scale-up and manufacturing, while Protect develops its pipeline for US and other global veterinary markets.

For an animal-health biotech, the arrangement moves a critical part of the commercial pathway outside the laboratory. Advanced biologics need reproducible cell lines, analytical development, manufacturing capacity and quality systems before they can progress through regulated markets. Bora brings those functions together across facilities in the United States and Taiwan, using a CHO-K1 cell-line platform and experience in antibodies and multispecific proteins.

The partnership is Bora’s first animal-health product collaboration. For Protect, it supplies a manufacturing partner while the company builds a broader development and partnership network across the United States, Europe and Asia. The companies have not identified the target diseases, financial terms or a product-launch timetable, so the announcement establishes a development and supply framework rather than a near-term commercial launch.

That distinction matters commercially. Antibody medicines can offer veterinary medicine a different approach from conventional small-molecule products or vaccines, but their route to market depends heavily on technical transfer, scalable production and consistent quality. Starting that work across several programmes at once could help Protect standardise its path through development; its eventual value will depend on clinical evidence, approvals and market adoption that have not yet been disclosed.

For Bora, the collaboration gives its licensed-supply platform an entry point into an animal-health segment that is seeking more sophisticated biologics. The company has positioned the agreement as a multi-project relationship rather than a one-off contract, which could make the collaboration a test case for further veterinary manufacturing work if the programmes advance.

For further information > Bora Biologics